
    
      An Open Label Phase III Study to Assess the Efficacy and Safety of Fixed-Dose Combination
      RHB-104 in Subjects with Active Crohn's Disease Despite 26 Weeks of Participation in the MAP
      US RHB-104-01 Study.
    
  